Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Teva to acquire Emalex Biosciences

Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor

Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics

Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Sun Pharma acquisition of Organon

Lucid Diligence Brief: Sun Pharma acquisition of Organon Professional audiences…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership

Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing

Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: 10x Genomics launches Atera Platform

Lucid Diligence Brief: 10x Genomics launches Atera Platform Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J

Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…


Privacy Preference Center